AstraZeneca PLC has forged its biggest deal in more than a decade, agreeing to pay up to US$6.9 billion to buy into a promising Japanese cancer treatment as part of its push to become a global oncology powerhouse.
AstraZeneca is to pay Japanese drugmaker Daiichi Sankyo Co Ltd US$1.35 billion upfront to jointly develop and commercialize the cancer therapy trastuzumab deruxtecan, with as much as US$5.6 billion in additional payments subject to sales milestones and other contingencies, the companies said late on Thursday.
They are also to equally split development and commercialization costs.
The deal fuels a race among big drug companies to develop effective — and lucrative — new cancer treatments.
With research breakthroughs like gene-editing and T-cell manipulation extending patients’ lives in unprecedented ways, the global market for cancer treatments has exploded to US$133 billion annually and become the fiercest battleground in pharmaceuticals.
AstraZeneca’s British rival GlaxoSmithKline PLC last month agreed to pay Germany’s Merck KGaA up to US$4.2 billion for access to a promising immune-oncology therapy.
AstraZeneca, headquartered in Cambridge, England, said that it would fund the transaction partly through a share sale of up to US$3.5 billion.
Daiichi’s treatment is one of the few in late-stage testing that could be a game-changer in the oncology landscape.
Projected to rake in US$7 billion annually at its peak, the treatment has been seen to double survival time for advanced breast cancer patients to 20 months, UBS Securities Japan Co analyst Atsushi Seki said.
“We believe that trastuzumab deruxtecan could become a transformative new medicine for the treatment of HER2 positive breast and gastric cancers,” AstraZeneca CEO Pascal Soriot said in a statement, adding that it has the potential to redefine breast cancer treatment.
The therapy combines a drug with a new delivery mechanism that applies chemotherapy selectively to cancer cells, minimizing systemic exposure to the patient.
Daiichi has already spent more than a decade developing the therapy before looking for a global partner, company executives said.
The transaction would not impact earnings this year, but will make a “significant contribution” by 2023, AstraZeneca said.
The partnership would add to shareholder value over the medium to long term, Daiichi said.
While the two companies are to split up the globe in booking sales — Daiichi is to take Japan, the US and parts of Europe, while AstraZeneca gets China, Australia, Canada and Russia — global profits are to be equally shared, they said.
The goal now is to get the treatment to patients.
Daiichi plans to submit its application to the US Food and Drug Administration by October and expects the regulator to reply in about 10 months, global head of oncology research and development Antoine Yver said.
BUSINESS UPDATE: The iPhone assembler said operations outlook is expected to show quarter-on-quarter and year-on-year growth for the second quarter Hon Hai Precision Industry Co (鴻海精密) yesterday reported strong growth in sales last month, potentially raising expectations for iPhone sales while artificial intelligence (AI)-related business booms. The company, which assembles the majority of Apple Inc’s smartphones, reported a 19.03 percent rise in monthly sales to NT$510.9 billion (US$15.78 billion), from NT$429.22 billion in the same period last year. On a monthly basis, sales rose 14.16 percent, it said. The company in a statement said that last month’s revenue was a record-breaking April performance. Hon Hai, known also as Foxconn Technology Group (富士康科技集團), assembles most iPhones, but the company is diversifying its business to
Apple Inc has been developing a homegrown chip to run artificial intelligence (AI) tools in data centers, although it is unclear if the semiconductor would ever be deployed, the Wall Street Journal reported on Monday. The effort would build on Apple’s previous efforts to make in-house chips, which run in its iPhones, Macs and other devices, according to the Journal, which cited unidentified people familiar with the matter. The server project is code-named ACDC (Apple Chips in Data Center) within the company, aiming to utilize Apple’s expertise in chip design for the company’s server infrastructure, the newspaper said. While this initiative has been
GlobalWafers Co (環球晶圓), the world’s No. 3 silicon wafer supplier, yesterday said that revenue would rise moderately in the second half of this year, driven primarily by robust demand for advanced wafers used in high-bandwidth memory (HBM) chips, a key component of artificial intelligence (AI) technology. “The first quarter is the lowest point of this cycle. The second half will be better than the first for the whole semiconductor industry and for GlobalWafers,” chairwoman Doris Hsu (徐秀蘭) said during an online investors’ conference. “HBM would definitely be the key growth driver in the second half,” Hsu said. “That is our big hope
The consumer price index (CPI) last month eased to 1.95 percent, below the central bank’s 2 percent target, as food and entertainment cost increases decelerated, helped by stable egg prices, the Directorate-General of Budget, Accounting and Statistics (DGBAS) said yesterday. The slowdown bucked predictions by policymakers and academics that inflationary pressures would build up following double-digit electricity rate hikes on April 1. “The latest CPI data came after the cost of eating out and rent grew moderately amid mixed international raw material prices,” DGBAS official Tsao Chih-hung (曹志弘) told a news conference in Taipei. The central bank in March raised interest rates by